Physician profile
Melissa Morrison
NPI 1356792410
$2,977.21
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.37 · 2022: $289 · 2023: $1,614 · 2024: $739 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $1,414 · Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $1,413.84 |
| Food and Beverage | $1,179.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $1,427.61 | 2023-2024 | Zimhi, Lucemyra |
| Abbvie INC. | $488.01 | 2023-2025 | |
| Indivior INC. | $208.13 | 2021-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $191.30 | 2021-2025 | |
| Alkermes, INC. | $149.92 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Braeburn INC. | $144.97 | 2024-2025 | Brixadi |
| Janssen Biotech, INC. | $76.77 | 2023 | Tecvayli |
| Janssen Pharmaceuticals, INC | $72.26 | 2022-2024 | Invega Trinza, Invega Sustenna |
| Axsome Therapeutics, INC. | $71.00 | 2024-2025 | Auvelity |
| Gilead Sciences, INC. | $47.75 | 2024 | |
| Biogen, INC. | $29.96 | 2024 | Zurzuvae |
| Abbott Laboratories | $28.64 | 2025 | Aveir |
| Vanda Pharmaceuticals INC. | $26.01 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.